Asklepian Consulting is a boutique consultancy exclusively focused on the strategic and commercial analysis of cell and gene therapies, regenerative medicines,
and biogerontological therapeutics
Asklepian Consulting CEO Dr Nafees N. Malik publishes five industry leading frameworks for the commercialisation of CAR T-cell and other advanced therapies:
Customer pyramid framework for CAR T-cell therapies in immuno-oncology (Drug Discov. Today 2016)
CAR T-cell therapies: formulation–product–proposition framework for commercialisation (Drug Discov. Today 2016)
Commercialisation of CAR T-cell therapies: business model spectrum (Drug Discov. Today 2017)
Reimbursement and adoption of advanced therapies: the 5-C framework (Regen. Med. 2014)
Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies (Regen. Med. 2016)
Asklepian Consulting CEO Dr Nafees N. Malik publishes first-ever manufacturing cost analysis of allogeneic vs autologous cell therapy:
Allogeneic versus autologous stem cell therapy: a comparison of manufacturing costs and commercialization challenges (BioPharm International 2012)
Asklepian Consulting CEO Dr Nafees N. Malik interviewed by RegMedNet.com: